Although in the study by Martini and coworkers [32], no statistically significant difference in plasma levels of TGF-β was observed in AD dogs during subcutaneous immunotherapy (SCIT), a tendency of decreasing concentration of this cytokine during therapy could be noted, which is similar to our results. The gene discussed is TGFB1; the disease is Alzheimer disease.